You are here

MOLECULAR TARGETING TECHNOLOGIES, INC.

Company Information
Address
833 LINCOLN AVE UNIT 9
WEST CHESTER, PA 19380-4471
United States


https://www.mtarget.com

Information

UEI: Y2FNW7N1V267

# of Employees: 6


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk

    Amount: $299,890.00

    We propose to develop a novel antithrombotic agent with improved efficacy and safety over standard of care via the following properties: 1) specific targeting to procoagulant surfaces, 2) high coagula ...

    STTRPhase I2023Department of Health and Human Services National Institutes of Health
  2. Instantaneous Tumor Spray for Real-Time Surgical Guidance

    Amount: $1,998,821.00

    Early stage ovarian cancer is typically asymptomatic. Undiagnosed until the disease has reached an advanced stage, the disease presents extensive intra-abdominal peritoneal metastases. Standard of car ...

    SBIRPhase II2022Department of Health and Human Services National Institutes of Health
  3. Topic 368: Biotherapy of Brain Tumors by Radioiodinated SapC-DOPS Nanovesicles

    Amount: $50,007.00

    There is an urgent need for more effective drug delivery agents for treatment of brain tumors, which are among the most aggressive and intractable cancers. SapC-DOPS, a nanovesicle composed of saposin ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  4. Sprayable, Prompt Color Changing Dye to Delineate Ovarian Cancer During Surgery

    Amount: $253,411.00

    Most ovarian cancer is not diagnosed until the disease has reached an advanced stage because the early stage disease is typically non symptomaticWhen diagnosedextensive intra abdominal metastases have ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  5. Topical Drug Treatment of Cutaneous Leishmaniasis

    Amount: $214,174.00

    Protozoan parasites of the genus Leishmania are the causative agents of leishmaniasis a disease that is characterized by a spectrum of clinical manifestations ranging from ulcerative skin lesions to ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  6. A PE-specific SPECT probe for the early detection of cancer treatment-induced cardiotoxicity.

    Amount: $224,819.00

    DESCRIPTION provided by applicant Although antitumor agents have resulted in significant survival benefits for cancer patients several agents have serious cardiovascular toxic side effects Anthra ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  7. IGF::OT::IGF SBIR Topic 85 To support the development of target specific molecular imaging agents in combination with existing imaging modalities to detect high risk atherosclerotic plaque.

    Amount: $222,581.00

    Not Available

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  8. Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists

    Amount: $219,935.00

    DESCRIPTION: Tracing neuronal connections with lipophilic carbocyanine dyes has revolutionized neuroanatomical tract tracing and is an essential feature to understand development of brain connections ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
  9. A novel vaccine: botulinum neurotoxin subunit on a viral carrier.

    Amount: $2,509,160.00

    DESCRIPTION (provided by applicant): According to the NIAID fact sheet on Botulism, the extreme toxicity of botulinum neurotoxins (BoNT) and the ease of production, transport, and delivery make this ...

    STTRPhase II2012Department of Health and Human Services National Institutes of Health
  10. Anionic Phospholipid-Selective PET/SPECT Agent for Infection Imaging

    Amount: $224,438.00

    DESCRIPTION (provided by applicant): Although a rapid and accurate diagnosis is crucial to the management of patients suspected of bacterial infection, the currently available radiopharmaceuticals are ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government